ArticleVox sanguinis2026
Investigating human platelet antigens and antibodies in pregnancy: An 11-year experience from a Canadian reference laboratory.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesFoetal and neonatal alloimmune thrombocytopaenia (FNAIT) is a potentially severe immune-mediated condition that is believed to be under-identified in the Canadian population. The Canadian Blood Services National Platelet Immunology Reference Laboratory (NPIRL) serves as a centralized referral laboratory for FNAIT investigations across Canada. Diagnostic evaluation includes human platelet antigen (HPA) genotyping and maternal anti-HPA antibody testing. This study is a review of all FNAIT investigations referred to NPIRL to assess testing patterns, antibody detection rates and evidence of under identification at a national level. MATERIALS AND
methodsAll maternal, paternal and neonatal samples related to FNAIT investigations between 20 January 2014 and 31 December 2024 were extracted from the NPIRL database. The geographic origin of samples, HPA genotyping and antibody specificity, if present, were documented.
resultsA total of 1986 samples (1076 maternal, 620 paternal and 290 neonatal) were received for FNAIT investigation over the 11-year study period. One-hundred and thirty-five HPA antibodies were identified in 130 of the maternal samples tested, with anti-HPA-1a and HPA-5b being the most frequently detected specificities. Despite a modest increase in annual referrals, the total number of investigations and antibody-positive cases was substantially lower than expected based on Canadian birth rates and published FNAIT incidence estimates.
conclusionReferral patterns and laboratory findings from NPIRL demonstrate a marked discrepancy between expected FNAIT incidence and observed diagnostic activity in Canada, indicating that FNAIT is substantially under-identified. These findings highlight the need for improved recognition, standardized investigation pathways and enhanced diagnostic strategies to reduce missed cases and improve neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.